OMER vs. NKTR, VNDA, ASMB, GBIO, OVID, ATOS, RIGL, RENB, GALT, and TRVI
Should you be buying Omeros stock or one of its competitors? The main competitors of Omeros include Nektar Therapeutics (NKTR), Vanda Pharmaceuticals (VNDA), Assembly Biosciences (ASMB), Generation Bio (GBIO), Ovid Therapeutics (OVID), Atossa Therapeutics (ATOS), Rigel Pharmaceuticals (RIGL), Renovaro (RENB), Galectin Therapeutics (GALT), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical preparations" industry.
Nektar Therapeutics (NASDAQ:NKTR) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, community ranking, dividends, risk, institutional ownership, profitability and valuation.
Omeros has a net margin of 0.00% compared to Omeros' net margin of -195.02%. Omeros' return on equity of -107.31% beat Nektar Therapeutics' return on equity.
75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 3.1% of Nektar Therapeutics shares are owned by insiders. Comparatively, 10.9% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Nektar Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Omeros has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.
In the previous week, Nektar Therapeutics had 9 more articles in the media than Omeros. MarketBeat recorded 14 mentions for Nektar Therapeutics and 5 mentions for Omeros. Omeros' average media sentiment score of 0.54 beat Nektar Therapeutics' score of 0.33 indicating that Nektar Therapeutics is being referred to more favorably in the media.
Omeros received 114 more outperform votes than Nektar Therapeutics when rated by MarketBeat users. Likewise, 71.80% of users gave Omeros an outperform vote while only 70.61% of users gave Nektar Therapeutics an outperform vote.
Omeros has lower revenue, but higher earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.
Nektar Therapeutics currently has a consensus price target of $3.50, suggesting a potential upside of 94.44%. Given Omeros' higher possible upside, analysts plainly believe Nektar Therapeutics is more favorable than Omeros.
Summary
Nektar Therapeutics and Omeros tied by winning 8 of the 16 factors compared between the two stocks.
Get Omeros News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OMER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
